Down 60%: Affymax Cuts to the Bone

Don't let it get away!

Keep track of the stocks that matter to you.

Help yourself with the Fool's FREE and easy new watchlist service today.

Affymax (NASDAQOTH: AFFY  ) has collapsed under the weight of a recall of its only product, Omontys. Shares are down 85% in 2013 as what once looked like a promising challenger to Amgen's (NASDAQ: AMGN  ) Epogen is beset by safety questions that could leave it permanently shelved.

Bizarrely shares of Affymax spiked more than 50% in a single day earlier this month, and despite no hard news backing the move, weary shareholders were hoping this was the beginning of a turnaround.

Unfortunately, that doesn't appear to be the case. Affymax fell another 64% today after disclosing that it was slashing its workforce dramatically and reiterating that it was looking at strategic options including bankruptcy. Amgen was up 2% as Omontys is stuck on the sidelines for the foreseeable future.

Health-care analyst David Williamson tackles the days news and spells out what it means for Affymax and investors.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long-term. The Motley Fool's free report, "3 Stocks That Will Help You Retire Rich," names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.

Read/Post Comments (0) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2321678, ~/Articles/ArticleHandler.aspx, 9/28/2016 2:51:03 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated Moments ago Sponsored by:
DOW 18,315.93 87.63 0.48%
S&P 500 2,167.33 7.40 0.34%
NASD 5,310.07 4.36 0.08%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/28/2016 12:24 PM
AFFY $0.07 Down +0.00 +0.00%
Affymax, Inc. CAPS Rating: **
AMGN $169.57 Down -2.06 -1.20%
Amgen CAPS Rating: ****
KERX $5.30 Up +0.13 +2.51%
Keryx Biopharmaceu… CAPS Rating: **